B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals.

about

B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals.

Item

http://www.wikidata.org/entity/Q38702009

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

B-13 progenitor-derived hepato ...... sponse to drugs and chemicals.

@en

type

Item

label

B-13 progenitor-derived hepato ...... sponse to drugs and chemicals.

@en

prefLabel

B-13 progenitor-derived hepato ...... sponse to drugs and chemicals.

@en

P1476

B-13 progenitor-derived hepato ...... esponse to drugs and chemicals

@en

P2093

Alistair C Leitch

http://www.w3.org/2001/XMLSchema#string

George E N Kass

http://www.w3.org/2001/XMLSchema#string

James A Shayman

http://www.w3.org/2001/XMLSchema#string

Philip M E Probert

http://www.w3.org/2001/XMLSchema#string

Stephanie K Meyer

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase

LXR, a nuclear receptor that defines a distinct retinoid response pathway

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

Drug induced phospholipidosis: an acquired lysosomal storage disorder

The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR

Exocrine pancreas trans-differentiation to hepatocytes--a physiological response to elevated glucocorticoid in vivo

Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges

Liver X receptors (LXR) as therapeutic targets in dyslipidemia.

Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid.

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

P304

120-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TOX.2017.05.014

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

386

http://www.w3.org/2001/XMLSchema#string

P50

Matthew C. Wright

P577

2017-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28552552

http://www.w3.org/2001/XMLSchema#string

P932

5553091

http://www.w3.org/2001/XMLSchema#string